{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T15:57:30Z","timestamp":1768924650460,"version":"3.49.0"},"reference-count":53,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100016145","name":"Ministerio de Sanidad, Consumo y Bienestar Social","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016145","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019608","name":"Lilly Oncology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019608","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["C1813\/A4853"],"award-info":[{"award-number":["C1813\/A4853"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000765","name":"University College London","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000765","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012317","name":"UCLH Biomedical Research Centre","doi-asserted-by":"publisher","award":["C444\/A15953"],"award-info":[{"award-number":["C444\/A15953"]}],"id":[{"id":"10.13039\/501100012317","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009647","name":"Ministry of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009647","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal-of-hepatology.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.jhep.2020.05.014","type":"journal-article","created":{"date-parts":[[2020,5,21]],"date-time":"2020-05-21T02:49:04Z","timestamp":1590029344000},"page":"1109-1117","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"title":["Landmark survival analysis and impact of anatomic site of origin in prospective clinical trials of biliary tract cancer"],"prefix":"10.1016","volume":"73","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2272-3678","authenticated-orcid":false,"given":"Mair\u00e9ad Geraldine","family":"McNamara","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1405-7337","authenticated-orcid":false,"given":"Andre","family":"Lopes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harpreet","family":"Wasan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7664-0130","authenticated-orcid":false,"given":"David","family":"Malka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Goldstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jenny","family":"Shannon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1729-807X","authenticated-orcid":false,"given":"Takuji","family":"Okusaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer J.","family":"Knox","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4728-7013","authenticated-orcid":false,"given":"Anna Dorothea","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thierry","family":"Andr\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Cunningham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Markus","family":"Moehler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0020-1537","authenticated-orcid":false,"given":"Lars Henrik","family":"Jensen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dieter","family":"Koeberle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tanios","family":"Bekaii-Saab","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9186-1604","authenticated-orcid":false,"given":"John","family":"Bridgewater","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1999-0863","authenticated-orcid":false,"given":"Juan W.","family":"Valle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2020.05.014_bib1","first-page":"11","article-title":"Cancer statistics, 2013","volume":"63","author":"Siegel","year":"2013","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.jhep.2020.05.014_bib2","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1055\/s-2004-828895","article-title":"Surgical management of cholangiocarcinoma","volume":"24","author":"Jarnagin","year":"2004","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.jhep.2020.05.014_bib3","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1080\/13651820801992542","article-title":"Surgery for cholangiocarcinoma: the role of liver transplantation","volume":"10","author":"Rosen","year":"2008","journal-title":"HPB (Oxford)"},{"key":"10.1016\/j.jhep.2020.05.014_bib4","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1432-2277.2010.01108.x","article-title":"Liver transplantation for cholangiocarcinoma","volume":"23","author":"Rosen","year":"2010","journal-title":"Transpl Int"},{"key":"10.1016\/j.jhep.2020.05.014_bib5","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1053\/j.gastro.2012.04.008","article-title":"Efficacy of neoadjuvant chemoradiation, followed by liver transplantation, for perihilar cholangiocarcinoma at 12 US centers","volume":"143","author":"Darwish","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2020.05.014_bib6","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","article-title":"Cisplatin plus gemcitabine vs. gemcitabine for biliary tract cancer","volume":"362","author":"Valle","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jhep.2020.05.014_bib7","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1038\/ng.3375","article-title":"Genomic spectra of biliary tract cancer","volume":"47","author":"Nakamura","year":"2015","journal-title":"Nat Genet"},{"key":"10.1016\/j.jhep.2020.05.014_bib8","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1161\/CIRCOUTCOMES.110.957951","article-title":"Landmark analysis at the 25-year landmark point","volume":"4","author":"Dafni","year":"2011","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1016\/j.jhep.2020.05.014_bib9","doi-asserted-by":"crossref","first-page":"4175","DOI":"10.1200\/JCO.2010.32.4343","article-title":"Conditional probability of survival in patients with newly diagnosed glioblastoma","volume":"29","author":"Polley","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jhep.2020.05.014_bib10","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/S1470-2045(12)70285-1","article-title":"Conditional survival of patients with metastatic renal-cell carcinoma treated with VEGF-targeted therapy: a population-based study","volume":"13","author":"Harshman","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jhep.2020.05.014_bib11","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s11060-014-1368-7","article-title":"Conditional probability of survival and post-progression survival in patients with glioblastoma in the temozolomide treatment era","volume":"117","author":"McNamara","year":"2014","journal-title":"J\u00a0Neurooncol"},{"key":"10.1016\/j.jhep.2020.05.014_bib12","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s12350-019-01624-z","article-title":"Landmark analysis: a primer","volume":"26","author":"Morgan","year":"2019","journal-title":"J\u00a0Nucl Cardiol"},{"key":"10.1016\/j.jhep.2020.05.014_bib13","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.hpb.2016.04.001","article-title":"Conditional probability of long-term survival after resection of hilar cholangiocarcinoma","volume":"18","author":"Buettner","year":"2016","journal-title":"HPB (Oxford)"},{"key":"10.1016\/j.jhep.2020.05.014_bib14","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1001\/jamasurg.2015.0219","article-title":"Conditional probability of long-term survival after liver resection for intrahepatic cholangiocarcinoma: a multi-institutional analysis of 535 patients","volume":"150","author":"Spolverato","year":"2015","journal-title":"JAMA Surg"},{"key":"10.1016\/j.jhep.2020.05.014_bib15","doi-asserted-by":"crossref","first-page":"4401","DOI":"10.1245\/s10434-016-5470-2","article-title":"Changing odds of survival over time among patients undergoing surgical resection of gallbladder carcinoma","volume":"23","author":"Buettner","year":"2016","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.jhep.2020.05.014_bib16","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1016\/j.hpb.2017.07.004","article-title":"Conditional survival in patients with unresectable perihilar cholangiocarcinoma","volume":"19","author":"Gaspersz","year":"2017","journal-title":"HPB (Oxford)"},{"key":"10.1016\/j.jhep.2020.05.014_bib17","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/s40880-017-0252-1","article-title":"Conditional survival in patients with gallbladder cancer","volume":"36","author":"Kim","year":"2017","journal-title":"Chin J Cancer"},{"key":"10.1016\/j.jhep.2020.05.014_bib18","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1038\/sj.bjc.6604628","article-title":"Gemcitabine and oxaliplatin in advanced biliary tract carcinoma: a phase II study","volume":"99","author":"Andr\u00e9","year":"2008","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jhep.2020.05.014_bib19","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1200\/JCO.2010.33.9473","article-title":"Multi-institutional phase II study of selumetinib in patients with metastatic biliary cancers","volume":"29","author":"Bekaii-Saab","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jhep.2020.05.014_bib20","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1186\/s12885-016-2174-8","article-title":"A\u00a0phase 1b study of selumetinib in combination with cisplatin and gemcitabine in advanced or metastatic biliary tract cancer: the ABC-04 study","volume":"16","author":"Bridgewater","year":"2016","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jhep.2020.05.014_bib21","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1007\/s00280-016-3089-4","article-title":"TACTIC: a multicentre, open-label, single arm phase II trial of panitumumab, cisplatin, and gemcitabine in biliary tract cancer","volume":"78","author":"Ferraro","year":"2016","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.jhep.2020.05.014_bib22","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1007\/s00280-010-1351-8","article-title":"Fixed-dose-rate gemcitabine combined with cisplatin in patients with inoperable biliary tract carcinomas","volume":"67","author":"Goldstein","year":"2011","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.jhep.2020.05.014_bib23","doi-asserted-by":"crossref","first-page":"2341","DOI":"10.1093\/annonc\/mds008","article-title":"Phase II marker-driven trial of panitumumab and chemotherapy in KRAS wild-type biliary tract cancer","volume":"23","author":"Jensen","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jhep.2020.05.014_bib24","doi-asserted-by":"crossref","first-page":"3702","DOI":"10.1200\/JCO.2008.16.5704","article-title":"Patient-reported outcomes of patients with advanced biliary tract cancers receiving gemcitabine plus capecitabine: a multicenter, phase II trial of\u00a0the Swiss Group for Clinical Cancer Research","volume":"26","author":"Koeberle","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jhep.2020.05.014_bib25","doi-asserted-by":"crossref","first-page":"448","DOI":"10.3109\/0284186X.2010.500300","article-title":"A\u00a0phase I-II dose escalation study of fixed-dose rate gemcitabine, oxaliplatin and capecitabine every two weeks in advanced cholangiocarcinomas","volume":"50","author":"Lassen","year":"2011","journal-title":"Acta Oncol"},{"key":"10.1016\/j.jhep.2020.05.014_bib26","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/S1470-2045(14)70212-8","article-title":"Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial","volume":"15","author":"Malka","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jhep.2020.05.014_bib27","doi-asserted-by":"crossref","first-page":"3125","DOI":"10.1016\/j.ejca.2014.09.013","article-title":"Gemcitabine plus sorafenib vs. gemcitabine alone in advanced biliary tract cancer: a double-blind placebo-controlled multicentre phase II AIO\u00a0study with biomarker and serum programme","volume":"50","author":"Moehler","year":"2014","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jhep.2020.05.014_bib28","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1038\/sj.bjc.6605779","article-title":"Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan","volume":"103","author":"Okusaka","year":"2010","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jhep.2020.05.014_bib29","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1159\/000336488","article-title":"HER2\/neu may not be an interesting target in biliary cancers: results of an early phase II study with lapatinib","volume":"82","author":"Peck","year":"2012","journal-title":"Oncology"},{"key":"10.1016\/j.jhep.2020.05.014_bib30","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1038\/sj.bjc.6602576","article-title":"Phase III study of 5FU, etoposide and leucovorin (FELV) compared to epirubicin, cisplatin and 5FU (ECF) in previously untreated patients with advanced biliary cancer","volume":"92","author":"Rao","year":"2005","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jhep.2020.05.014_bib31","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ejca.2017.12.028","article-title":"PICCA study: panitumumab in combination with cisplatin\/gemcitabine chemotherapy in KRAS wild-type patients with biliary cancer-a randomised biomarker-driven clinical phase II AIO study","volume":"92","author":"Vogel","year":"2018","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jhep.2020.05.014_bib32","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1038\/sj.bjc.6605377","article-title":"Gemcitabine, oxaliplatin and 5-FU in advanced bile duct and gallbladder carcinoma: two parallel, multicentre phase-II trials","volume":"101","author":"Wagner","year":"2009","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jhep.2020.05.014_bib33","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1093\/annonc\/mdv483","article-title":"Prognostic factors for progression-free and overall survival in advanced biliary tract cancer","volume":"27","author":"Bridgewater","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jhep.2020.05.014_bib34","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1186\/s12885-017-3266-9","article-title":"Systemic therapy in younger and elderly patients with advanced biliary cancer: sub-analysis of ABC-02 and twelve other prospective trials","volume":"17","author":"McNamara","year":"2016","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jhep.2020.05.014_bib35","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/S1470-2045(15)00139-4","article-title":"Cediranib or placebo in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer (ABC-03): a\u00a0randomised phase 2 trial","volume":"16","author":"Valle","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jhep.2020.05.014_bib36","doi-asserted-by":"crossref","first-page":"2588","DOI":"10.1200\/JCO.2015.61.6953","article-title":"Biliary tract cancers: finding better ways to lump and split","volume":"33","author":"Kelley","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jhep.2020.05.014_bib37","doi-asserted-by":"crossref","first-page":"3838","DOI":"10.1002\/cncr.30254","article-title":"Biliary cancer: utility of next-generation sequencing for clinical management","volume":"122","author":"Javle","year":"2016","journal-title":"Cancer"},{"key":"10.1016\/j.jhep.2020.05.014_bib38","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1038\/ng.3030","article-title":"Whole-exome and targeted gene sequencing of gallbladder carcinoma identifies recurrent mutations in the ErbB pathway","volume":"46","author":"Li","year":"2014","journal-title":"Nat Genet"},{"key":"10.1016\/j.jhep.2020.05.014_bib39","doi-asserted-by":"crossref","first-page":"6997","DOI":"10.1038\/ncomms7997","article-title":"APOBEC family mutational signatures are associated with poor prognosis translocations in multiple myeloma","volume":"6","author":"Walker","year":"2015","journal-title":"Nat Commun"},{"key":"10.1016\/j.jhep.2020.05.014_bib40","doi-asserted-by":"crossref","first-page":"3924","DOI":"10.1038\/s41388-018-0245-9","article-title":"APOBEC3B and APOBEC mutational signature as potential predictive markers for immunotherapy response in non-small cell lung cancer","volume":"37","author":"Wang","year":"2018","journal-title":"Oncogene"},{"key":"10.1016\/j.jhep.2020.05.014_bib41","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S1470-2045(20)30109-1","article-title":"Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study","volume":"21","author":"Abou-Alfa","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jhep.2020.05.014_bib42","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/S1470-2045(20)30157-1","article-title":"Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study","volume":"21","author":"Abou-Alfa","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jhep.2020.05.014_bib43","first-page":"200","article-title":"Advanced intrahepatic cholangiocarcinoma: post-hoc analysis of the ABC-01, -02 and -03 clinical trials","volume":"112","author":"Lamarca","year":"2020","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.jhep.2020.05.014_bib44","doi-asserted-by":"crossref","first-page":"e65144","DOI":"10.1371\/journal.pone.0065144","article-title":"Gene expression profiling of ampullary carcinomas classifies ampullary carcinomas into biliary-like and intestinal-like subtypes that are prognostic of outcome","volume":"8","author":"Overman","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.jhep.2020.05.014_bib45","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1038\/s41416-019-0415-8","article-title":"Can we classify ampullary tumours better? Clinical, pathological and\u00a0molecular features. Results of an AGEO study","volume":"120","author":"Perkins","year":"2019","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jhep.2020.05.014_bib46","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1016\/j.celrep.2017.02.033","article-title":"Integrative genomic analysis of cholangiocarcinoma identifies distinct IDH-mutant molecular profiles","volume":"18","author":"Farshidfar","year":"2017","journal-title":"Cell Rep"},{"key":"10.1016\/j.jhep.2020.05.014_bib47","doi-asserted-by":"crossref","first-page":"751","DOI":"10.21037\/jgo.2019.03.10","article-title":"Frequency and prognostic significance of isocitrate dehydrogenase 1 mutations in cholangiocarcinoma: a systematic literature review","volume":"10","author":"Boscoe","year":"2019","journal-title":"J\u00a0Gastrointest Oncol"},{"key":"10.1016\/j.jhep.2020.05.014_bib48","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1002\/cncr.22902","article-title":"Expanded phase II trial of gemcitabine and capecitabine for advanced biliary cancer","volume":"110","author":"Riechelmann","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.jhep.2020.05.014_bib49","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1093\/annonc\/mdz058","article-title":"Capecitabine plus oxaliplatin vs. gemcitabine plus oxaliplatin as first-line therapy for advanced biliary tract cancers: a multicentre, open-label, randomized, phase III, noninferiority trial","volume":"30","author":"Kim","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jhep.2020.05.014_bib50","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1001\/jamaoncol.2019.0270","article-title":"Gemcitabine, cisplatin, and nab-paclitaxel for the treatment of advanced biliary tract cancers: a phase 2 clinical trial","volume":"5","author":"Shroff","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jhep.2020.05.014_bib51","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1093\/annonc\/mdz403","article-title":"Impact of age and gender on the safety and efficacy of chemotherapy plus bevacizumab in metastatic colorectal cancer: a pooled analysis of TRIBE and TRIBE2 studies","volume":"30","author":"Marmorino","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jhep.2020.05.014_bib52","doi-asserted-by":"crossref","first-page":"v28","DOI":"10.1093\/annonc\/mdw324","article-title":"Biliary cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"27","author":"Valle","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jhep.2020.05.014_bib53","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1016\/j.celrep.2019.03.088","article-title":"Establishment of patient-derived organoids and drug screening for biliary tract carcinoma","volume":"27","author":"Saito","year":"2019","journal-title":"Cell Rep"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827820303068?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827820303068?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T17:46:03Z","timestamp":1764611163000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827820303068"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":53,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["S0168827820303068"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2020.05.014","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Landmark survival analysis and impact of anatomic site of origin in prospective clinical trials of biliary tract cancer","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2020.05.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}